liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
Nuclear expression of the RNA-binding protein RBM3 is associated with an improved clinical outcome in breast cancer
Lund University, Malmo University Hospital, Department Lab Med, Centre Mol Pathol, SE-20502 Malmo, Sweden Lund University, CREATE Hlth Centre Translat Canc Research, SE-20502 Malmo, Sweden .
University Coll Dublin, Sch Biomol and Biomed Science, Conway Institute, Dublin 2, Ireland .
Lund University, Div Surg, Department Clin Science, SE-20502 Malmo, Sweden .
Uppsala University, Department Genet and Pathol, Rudbeck Lab, Uppsala, Sweden .
Show others and affiliations
2009 (English)In: Modern Pathology, ISSN 0893-3952, E-ISSN 1530-0285, Vol. 22, no 12, 1564-1574 p.Article in journal (Refereed) Published
Abstract [en]

Single-strand RNA-binding proteins (RBPs) are involved in many aspects of RNA metabolism and in the regulation of gene transcription. The RBP RBM3 was recently suggested to be a proto-oncogene in colorectal cancer; however, such a role has not been corroborated by previous studies in the colon or other tumor types, and the prognostic implications of tumor-specific RBM3 expression remain unclear. Mono-specific antibodies against RBM3 were generated. Antibody specificity was confirmed using siRNA gene silencing, western blotting and immunohistochemistry on a panel of breast cancer cell lines. Using tissue microarrays and IHC, RBM3 protein expression was examined in 48 normal tissues and in 20 common cancers. Additional analysis in two independent breast cancer cohorts (n = 1016) with long-term follow-up was also carried out. RBM3 was upregulated in cancer compared to normal tissues. The nuclear expression of RBM3 in breast cancer was associated with low grade (Pandlt;0.001), small tumors (Pandlt;0.001), estrogen receptor (ER) positivity (Pandlt;0.001) and Ki-67 negativity (Pandlt;0.001) in both the breast cancer cohorts. An increased nuclear expression of RBM3 was associated with a prolonged overall and recurrence-free survival. The prognostic value was particularly pronounced in hormone receptor-positive tumors and remained significant in multivariate interaction analysis after controlling for tamoxifen treatment (HR: 0.49, 95% CI: 0.30-0.79, P = 0.004). These data strongly indicate that nuclear RBM3 is an independent favorable prognostic factor in breast cancer, and seems to have a specific role in ER-positive tumors.

Place, publisher, year, edition, pages
Nature Publishing Group, 2009. Vol. 22, no 12, 1564-1574 p.
Keyword [en]
RBM3, breast cancer, prognosis, estrogen receptor, antibody-based proteomics
National Category
Cancer and Oncology
URN: urn:nbn:se:liu:diva-52780DOI: 10.1038/modpathol.2009.124ISI: 000272207200006PubMedID: 19734850OAI: diva2:285544
Available from: 2010-01-12 Created: 2010-01-12 Last updated: 2015-11-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Stål, Olle
By organisation
OncologyFaculty of Health SciencesDepartment of Oncology UHL
In the same journal
Modern Pathology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 61 hits
ReferencesLink to record
Permanent link

Direct link